ReviewExpert review of vaccines2013
Immunological assessment of influenza vaccines and immune correlates of protection.
Review in Expert review of vaccines, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06738082 (Influenza Vaccine Elicited Immune Response in Immunocompromised Patients), which is not on this map. Cited by 93 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Influenza Vaccine Elicited Immune Response in Immunocompromised Patients
Who cites it
93 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Vaccines for the prevention of seasonal influenza in patients with diabetes: systematic review and meta-analysis.BMC medicine · 2015Pooled it
- Pooled it
- Optimized seasonal influenza mRNA vaccine compositions demonstrate safety and enhanced immunogenicity in a phase 2 study.Human vaccines & immunotherapeutics · 2026Trial
- Phase 1/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adults.Human vaccines & immunotherapeutics · 2026Trial
- Coadministration of mRNA-1345 RSV vaccine with high-dose quadrivalent influenza vaccine in adults aged 65 and older: An observer-blinded, placebo-controlled, randomized, phase 3 trial.Human vaccines & immunotherapeutics · 2026Trial
- An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers.Human vaccines & immunotherapeutics · 2025Trial
- A Randomized Controlled Trial to Compare Immunogenicity to Cell-Based Versus Live-Attenuated Influenza Vaccines in Children.Journal of the Pediatric Infectious Diseases Society · 2023Trial
- Trial
- Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.Frontiers in immunology · 2018Trial
- Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial.BMC infectious diseases · 2017Trial
- Trial
- Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial.Clinical and vaccine immunology : CVI · 2016Trial
- Safety and immunogenicity of influenza whole inactivated virus vaccines: A phase I randomized clinical trial.Human vaccines & immunotherapeutics · 2015Trial
- Detection of antibodies to avian influenza virus H5N1 clade 2.3.4.4b in naturally infected cattle for more than a year.Scientific reports · 2026Article
- T-cell-mediated immunity to influenza A (H2N3): implications for caccine efficacy and cross-subtype protection.Archives of microbiology · 2026Review
- Immune history confers antibody- and T cell-dependent cross-protection against highly pathogenic avian influenza H5N1 viruses.Journal of virology · 2026Article
- Article
- Intranasal hemagglutinin protein boosters induce protective mucosal immunity against influenza A viruses in mice.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Repeated oral exposure to H5N1 influenza virus in pasteurized milk does not cause adverse responses to subsequent influenza infection.Science advances · 2025Article
- Assessment of Cross-Reactive Neutralizing Antibodies Induction Against H5N1 Clade 2.3.4.4b by Prior Seasonal Influenza Immunization in Retail Workers.Open forum infectious diseases · 2025Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Influenza vaccines remain the primary public health tool in reducing the ever-present burden of influenza and its complications. In seeking more immunogenic, more effective and more broadly cross-protective influenza vaccines, the landscape of influenza vaccines is rapidly expanding, both in near-term advances and next-generation vaccine design. Although the first influenza vaccines were licensed over 60 years ago, the hemagglutination-inhibition antibody titer is currently the only universally accepted immune correlate of protection against influenza. However, hemagglutination-inhibition titers appear to be less effective at predicting protection in populations at high risk for severe influenza disease; older adults, young children and those with certain medical conditions. The lack of knowledge and validated methods to measure alternate immune markers of protection against influenza remain a substantial barrier to the development of more immunogenic, broadly cross-reactive and effective influenza vaccines. Here, the authors review the knowledge of immune effectors of protection against influenza and discuss assessment methods for a broader range of immunological parameters that could be considered in the evaluation of traditional or new-generation influenza vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.